David Lewis

Morgan Stanley Upgrades Medtronic On Exposure To COVID-19 Recovery

COVID-19 Testing Stocks Move Lower After Abbott Receives EUA For 15-Minute Test

Morgan Stanley Says Edwards Lifesciences Settlement With Abbott An 'Expensive Positive'

COVID-19 Testing Stocks Move Lower After Abbott Receives EUA For 15-Minute Test

Morgan Stanley Says Edwards Lifesciences Settlement With Abbott An 'Expensive Positive'

Analysts Constructive On Intuitive Surgical Following Solid Quarter

Analysts, Investors Like Johnson & Johnson's Improvement, But Lawsuits Loom

Analysts Constructive On Intuitive Surgical Following Solid Quarter

|

Analysts, Investors Like Johnson & Johnson's Improvement, But Lawsuits Loom

|

Sell-Side Positive On Johnson & Johnson's Unexpected Ohio Opioid Settlement

|

Why One Johnson & Johnson Analyst Sees Oklahoma Opioid Ruling As Near-Term Sentiment Positive

|

David Lewis Recent News

Intuitive Surgical's Q2 Performance Lauded By Bullish Analysts

|

After Earnings Beat, Wall Street Talks Johnson & Johnson Litigation Risk

|

Morgan Stanley: Medtronic's $4B Financing Could Be 10-Cent EPS Tailwind

|

Johnson & Johnson Analysts Laud Accelerating Pharma Business

|

Analysts View Johnson & Johnson's Organic Growth Guidance As Conservative

|

Analysts Unfazed By Intuitive Surgical's Higher Opex Guidance

|

Analysts Stand By Johnson & Johnson Despite Earnings Pullback

|

Morgan Stanley Finds A Few Reasons To Double Upgrade Baxter

|

Morgan Stanley Downgrades Hologic On Tough Cynosure Recovery, Surgery Business Risks

|

Johnson & Johnson's Asbestos Woes: Experts Speak Up

|

3 Reasons Why Nevro Corp. Was Downgraded By Morgan Stanley

|

Analyst: Intuitive Surgical Is Moving Into Its 'Most Catalyst Rich' Cycle Ever

|

Abbott Labs Has 'An Emerging Picture Of Top-Tier Growth,' Says Morgan Stanley

|

Morgan Stanley Turns Bullish On Haemonetics

|

On The Detroit River, America's Only Floating Post Office Blends Tradition And Technology

|

Intuitive Surgical's Sp Ushers In The Next Phase Of Growth Story

|

Here's Every Sell-Side Rating Following iRhythm's IPO Quiet Period Expiration

|

Hill-Rom Story Not Appreciated By Wall Street, Says Morgan Stanley

|

Nevro Has A Multi-Billion Dollar Opportunity

|

Johnson & Johnson Sales Fall: What The Street Is Saying Now

|

Everyone's Talking About ROLARR Heading Into Intuitive Surgical Earnings: Here's What It Means

|

Johnson & Johnson Faces Pressure From U.S. Patent Office

|

UPDATE: Morgan Stanley Initiates Coverage On Intuitive Surgical

|